Skip to main content
EYSUVIS® (loteprednol etabonate ophthalmic suspension) home page

Hello,
rapid* relief!

If you’re ready for relief, it’s time to learn about EYSUVIS and how it can help you during flare‑ups.

TREATS SIGNS + SYMPTOMS

Proven to relieve scratching, burning, redness, and overall discomfort

GOES TO THE SOURCE

Delivers medication right to the source of the inflammation that causes symptom flare‑ups

WORKS FAST*

Designed to take on symptom flare‑ups with fast‑acting relief

Safety & side effects

The most common side effect of EYSUVIS was pain when the eye drops are put in the eye. This is not the only possible side effect. Be sure to tell your eye doctor if you have any side effects that bother you.

DO NOT use EYSUVIS if you have an infection in your eye. To help avoid infection, don’t let the dropper tip touch your eye or any other surface.

You’re encouraged to report negative side effects of prescription drugs to the FDA.

Visit , or call 1‑800‑FDA‑1088.

EYSUVIS® (loteprednol etabonate ophthalmic suspension) dropper and packaging

How EYSUVIS works

EYSUVIS can be taken for up to 14 days at a time to soothe uncomfortable redness, burning, scratching, tearing, and blurred vision from dry eye flares.

EYSUVIS contains a steroid called loteprednol etabonate (LO‑tuh‑PRED‑nal e‑TAB‑uh‑NATE) that targets inflammation — a key cause of dry eye symptom
flare‑ups.

EYSUVIS treats the source of dry eye symptom flare‑ups using a proprietary technology to deliver safe and manageable doses of anti‑inflammatory medication where you need it.

Taking Eysuvis

Contact us

For additional information or to report an adverse event, call Kala Pharmaceuticals, Inc. at 1‑833‑287‑KALA
(1‑833‑287‑5252).

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit , or call 1‑800‑FDA‑1088.

Sign up for updates

Want to know more about EYSUVIS? Register your email to get updates and information on the drop that’s there for the flare.

* In a clinical trial program with 2871 patients with dry eye, patients using EYSUVIS showed significant reduction in the symptoms of dry eye (ocular discomfort) as early as Day 4 after starting treatment (versus placebo). Symptoms continued to improve up to the end of the treatment period (Day 15). Patients taking EYSUVIS also showed significant reduction in signs of dry eye (eye redness) at Day 15 versus placebo.